WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001030843) LIGAND ACTIVATED TRANSCRIPTIONAL REGULATOR PROTEINS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/030843    International Application No.:    PCT/EP2000/010430
Publication Date: 03.05.2001 International Filing Date: 23.10.2000
Chapter 2 Demand Filed:    17.04.2001    
IPC:
A61K 48/00 (2006.01), C07K 14/47 (2006.01), C07K 14/705 (2006.01), C07K 14/72 (2006.01), C12N 15/63 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US)
Inventors: BARBAS, Carlos, F.; (US).
KADAN, Michael; (US).
BEERLI, Roger; (CH)
Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH)
Priority Data:
09/433,042 25.10.1999 US
09/586,625 02.06.2000 US
Title (EN) LIGAND ACTIVATED TRANSCRIPTIONAL REGULATOR PROTEINS
(FR) PROTEINES DE REGULATEUR DE TRANSCRIPTION ACTIVEES PAR UN LIGAND
Abstract: front page image
(EN)Fusion proteins for use as ligand-dependent transcriptional are provided. The fusion proteins include a nucleotide binding domain operatively linked to a ligand-binding domain. They also can include a transcription regulating domain. The nucleotide binding domain is a zinc-finger peptide that binds to a targeted contiguous nucleotide sequence of from 3 to 18 nucleotides are provided. The fusion proteins are used for gene therapy. Also provided are polynucleotides encoding the fusion proteins, expression vectors, and transfected cells.
(FR)L'invention concerne des protéines de fusion s'utilisant comme régulateurs de transcription. Ces protéines de fusion contiennent un domaine de liaison aux nucléotides lié de manière fonctionnelle à un domaine de liaison aux ligands. Elles contiennent également un domaine de régulation de la transcription. Le domaine de liaison aux nucléotides est un peptide à doigts de zinc qui se lie à une séquence nucléotidique contiguë ciblée comprenant entre 3 et 18 nucléotides. Les protéines de fusion de l'invention s'utilisent pour la thérapie génique. L'invention concerne enfin les polynucléotides codant pour lesdites protéines de fusion, les vecteurs d'expression et les cellules transfectées.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)